Edesa Biotech Paridiprubart Phase 3 Shows 27% Mortality Reduction in 278 Patients
In a 278-patient Phase 3 trial, paridiprubart cut 28-day mortality to 24% from 33%, a 27% relative reduction (p<0.001), with consistent benefits across IMV, non-IMV and key comorbidities. Edesa filed provisional patents covering sepsis, acute kidney injury and pneumonia indications while evaluating strategic partnerships.
1. Phase 3 Trial Results
Edesa’s Phase 3 study enrolled 278 patients randomized 1:1 to paridiprubart plus standard of care or placebo. The treatment arm achieved a 24% 28-day mortality rate versus 33% for placebo, representing a 27% relative risk reduction (p<0.001) and a higher rate of clinical improvement by Day 28.
2. Exploratory Comorbidity Analyses
In the 174-patient non-IMV subgroup, mortality fell to 15% versus 23% (35% relative reduction; p<0.05). Exploratory cohorts with acute kidney injury (n=48), sepsis (n=41) and pneumonia (n=108) showed mortality reductions of 35%, 36% and 30% respectively (all p<0.05), underscoring broad benefit.
3. Intellectual Property Strategy
Based on these data, Edesa filed provisional U.S. patent applications for paridiprubart’s use in sepsis, acute kidney injury and pneumonia, complementing existing composition-of-matter patents that extend into the 2030s.
4. Next Steps and Collaborations
Edesa plans manufacturing scale-up and is in advanced discussions for strategic partnerships to support late-stage development and commercialization. A separate U.S. government-funded ARDS study with up to 200 subjects is ongoing, and results will be presented at ATS 2026.